Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Period	fcf
2015-12-31	-$41.75M
2016-12-31	-$4.92M
2017-12-31	-$14.93M
2018-12-31	-$11.89M
2019-12-31	-$13.86M
2020-12-31	-$15.21M
2021-12-31	-$28.91M
2022-12-31	-$28.42M
2023-12-31	-$39.53M
2024-12-31	-$47.27M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ELDN	$3.13	+2.46%	1.03M
3
4
5

Eledon Pharmaceuticals Inc. (ELDN) Free Cash Flow

Free Cash Flow Data

Get Eledon Pharmaceuticals Inc. Data in Excel

More ELDN Financial Data